Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

PROTAC Drugs in Cancer Care (2024) Fasching P Journal article Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2024) Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C, Klare P, et al. Journal article Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis (2024) Untch M, Pérol D, Mayer EL, Cortes J, Nusch A, Cameron D, Barrios C, et al. Journal article Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer (2024) Gaß P, Thiel FC, Häberle L, Ackermann S, Theuser AK, Hummel N, Boehm S, et al. Journal article Ribociclib plus Endocrine Therapy in Early Breast Cancer (2024) Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, et al. Journal article Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany (2024) Lugnier C, Sommerlatte S, Attenberger U, Beer AJ, Bentz M, Benz SR, Birkner T, et al. Journal article Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence (2024) Fasching P, Kreipe H, Del Mastro L, Ciruelos E, Freyer G, Korfel A, Chouaki N, et al. Journal article, Review article Spatial expression of claudin 18.2 in matched primaries and metastases of tubo-ovarian carcinoma of all subtypes (2024) Wagner P, Gaß P, Pöschke P, Eckstein M, Gloßner L, Hartmann A, Beckmann M, et al. Journal article Association between event-free survival and overall survival in early-stage triple-negative breast cancer (2024) Huang M, Fasching P, Haiderali A, Xue W, Pan W, Karantza V, Yang F, et al. Journal article, Review article Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer (2024) Fasching P, Decker T, Hartkopf A, Nusch A, Heinrich BJ, Kurbacher C, Fuchs R, et al. Journal article